Rheumatoid arthritis itself is not directly fatal, but it shortens life expectancy by roughly 6 to 7 years on average, and in people with long-established disease, that gap widens to 8 to 10 years. The excess deaths come not from joint damage itself but from complications the disease drives throughout the body, especially in the heart, lungs, and immune system. Modern treatments have improved survival significantly, yet people with RA still die earlier than the general population.
How RA Shortens Life Expectancy
RA is a systemic inflammatory disease, meaning the same immune overactivity that attacks your joints also affects blood vessels, organs, and tissues far from any joint. Chronic inflammation accelerates damage to artery walls, stiffens lung tissue, and makes the immune system less effective at fighting real infections. Over years or decades, these effects accumulate into life-threatening conditions that wouldn’t have developed, or would have developed much later, in someone without RA.
An Australian long-term cohort study found that patients diagnosed in the early 1990s lost a median of 6 years (men) to 7 years (women) of life expectancy within a 14-year follow-up period. Those with more established disease at the time of the study fared worse, losing 8 to 10 years. The key takeaway: the longer inflammation runs poorly controlled, the greater the toll on survival.
Cardiovascular Disease Is the Leading Killer
The single biggest driver of early death in RA is cardiovascular disease, particularly heart attacks. RA patients are roughly twice as likely to experience a “silent” heart attack, one that causes damage without classic chest pain and often goes undiagnosed until imaging picks it up later. The risk of sudden cardiac death is also nearly double that of age-matched people without RA.
What makes this especially dangerous is that standard heart risk calculators underestimate the threat. Traditional risk factors like high cholesterol and high blood pressure matter, but RA adds an independent layer of risk through chronic inflammation. Inflammatory markers that rheumatologists track, such as markers of joint swelling and blood vessel inflammation, turn out to be significant predictors of cardiovascular events even after accounting for the usual risk factors. This is why managing RA inflammation aggressively does more than protect your joints. It protects your heart.
Lung Complications
Interstitial lung disease (ILD), a condition where lung tissue becomes scarred and stiff, affects a substantial number of RA patients. Some estimates suggest lung involvement of varying severity occurs in up to 40% of people with RA, though many cases are mild and detected only on imaging. When ILD does become clinically significant, it restricts breathing capacity and can progress to respiratory failure.
The outlook for RA-related ILD is considerably better than for other forms of lung scarring. A UK study found that 5-year survival for RA-associated ILD was 87.5%, compared to just 40% for idiopathic pulmonary fibrosis, a similar-looking condition with no known cause. Still, lung disease remains one of the top contributors to RA mortality, particularly in patients with poorly controlled inflammation over many years.
Infection Risk
RA creates a double vulnerability to infections. The disease itself dysregulates the immune system, and many of the medications used to treat it deliberately suppress immune activity. A large meta-analysis found that patients on biologic therapies had a 31% higher risk of serious infections compared to those on older, conventional medications. In absolute terms, that translates to about six additional serious infections per 1,000 patients treated per year.
The risk is highest in the first 6 to 12 months after starting a biologic medication, then tends to level off. This doesn’t mean these drugs are too dangerous to use. Uncontrolled RA inflammation carries its own infection risk, and the cardiovascular and organ damage from undertreated disease is typically far more dangerous than the modest increase in infection rates from treatment. But it does mean that infections like pneumonia and sepsis remain a meaningful cause of death in RA patients, and staying current on vaccinations and seeking prompt treatment for fevers or infections matters more than it does for the average person.
Rare but Serious Complications
Two uncommon complications deserve mention because they can be fatal when they occur.
The first is cervical spine instability. RA can erode the small joints at the top of the spine where the neck meets the skull, causing the top two vertebrae to slip out of alignment. In extreme cases, this compresses the brainstem and can cause sudden death. Historically, postmortem studies found this in about 10% of cervical RA patients, and the prevalence of this instability has dropped from around 36% before 1980 to about 24% in more recent decades, likely due to better disease control. Sudden death from this complication is genuinely rare in the modern era, with only a handful of documented cases per decade.
The second is AA amyloidosis, a condition where years of uncontrolled inflammation cause an abnormal protein to deposit in organs, especially the kidneys. Before 2010, prevalence rates in RA patients ranged from about 17% to 25%. After the widespread adoption of biologic therapies, that figure plummeted to under 1%. This is one of the clearest examples of how modern treatment has eliminated a once-common fatal complication.
Why Antibody Status Matters
Not all RA carries the same mortality risk. Blood tests for rheumatoid factor (RF) and anti-CCP antibodies help predict disease severity, and they also correlate with survival. Patients who test positive for RF alone have roughly double the mortality rate of those who test negative for both antibodies. Patients positive for both RF and anti-CCP have about a 66% increase in mortality, while those positive only for anti-CCP have a smaller, statistically less certain increase of around 30%.
These numbers reflect the fact that seropositive RA tends to be more aggressive, with more joint erosion, more systemic inflammation, and more organ involvement. If you know your antibody status, it gives both you and your rheumatologist useful information about how closely to monitor for complications.
How Modern Treatment Has Changed the Picture
The survival gap between RA patients and the general population has narrowed since biologic therapies became available in the late 1990s. The near-disappearance of amyloidosis, the reduced rates of cervical spine complications, and better cardiovascular awareness have all contributed. A 2019 study reported 5-year survival of 80% among RA patients, which, while improved, still falls short of what would be expected in the general population of the same age.
Controlling inflammation alone hasn’t been enough to fully close the gap. Residual risk from cardiovascular disease persists even in patients whose joint symptoms are well managed, suggesting that factors like cumulative damage from earlier years of active disease, medication side effects, and the metabolic changes RA causes all play a role. The practical implication is that RA management needs to go beyond joint symptoms. Monitoring blood pressure, cholesterol, and lung function matters just as much for long-term survival as keeping joints from swelling.